Melanocortin Peptide

PT-141

Bremelanotide • Sexual Desire & Central Arousal Support

PT-141 is a melanocortin receptor agonist researched for sexual desire and arousal. Unlike PDE5 inhibitors, it acts primarily through central nervous system pathways rather than directly through vascular mechanisms.

Sexual Health Injectable Investigational Nasal

Protocol Snapshot

Quick reference before the deep dive

Verified Vendors

PT-141

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Approved Dose

1.75mg

Subcutaneous, as needed

Timing

45+ min

Before anticipated activity

Half-Life

~2.7 hrs

Bremelanotide terminal half-life

Use Limit

1 per 24 hrs

Maximum 8 doses per month

Peptide Grade

GradeB

Two randomized Phase 3 trials and an FDA-approved 1.75mg product support use for acquired generalized HSDD in premenopausal women. Modest average benefit, frequent nausea, transient blood-pressure effects, and weaker evidence for men or nasal use limit the grade.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is PT-141?

PT-141, or bremelanotide, is a seven-amino-acid cyclic peptide derived from Melanotan II. It activates melanocortin receptors and was developed to study centrally mediated sexual desire and arousal without relying on the direct PDE5 pathway used by sildenafil or tadalafil.

Bremelanotide engages several melanocortin receptor subtypes. Central melanocortin signaling is considered important to its effects, but the exact mechanism by which the approved drug improves HSDD remains unknown.

Its evidence is route- and population-specific: the strongest data support the approved subcutaneous product in premenopausal women with acquired, generalized HSDD. Male erectile-function studies and older intranasal trials are smaller and do not establish equivalent dosing across routes.

Central Rather Than PDE5 Signaling

PT-141 targets melanocortin signaling involved in desire and arousal. PDE5 inhibitors act more directly on the vascular mechanics of erection, so the two approaches are related to different parts of sexual response.

Benefits & Clinical Evidence

Acquired Generalized HSDD

Two Phase 3 RECONNECT trials found statistically significant improvements in sexual desire and related distress in the studied premenopausal population, although the average benefit was modest.

Central Arousal Signaling

Bremelanotide activates melanocortin receptors rather than directly increasing testosterone, estrogen, or penile blood flow. Its exact therapeutic mechanism remains incompletely defined.

Male ED Research

Early intranasal studies reported erectile responses in some men with ED, including sildenafil nonresponders. These findings are preliminary and did not lead to an approved male indication.

As-Needed Administration

The approved product uses a fixed 1.75mg subcutaneous dose at least 45 minutes before anticipated activity rather than a daily or multiweek cycle.

Protocol Planning

Dosing and route-specific preparation

Protocol Planning & Dosing

PT-141 is used as needed rather than as a daily cycle. The approved Vyleesi label provides a fixed subcutaneous regimen; lower compounded amounts are community practice and should not be presented as an established alternative protocol.

Approved Vyleesi Use

Dose

1.75mg subcutaneously

Timing

At least 45 minutes before anticipated activity

Maximum

One dose per 24 hours and no more than 8 doses per month

Site

Abdomen or thigh

Community Lower-Dose Context

Start

0.5mg is often discussed to assess nausea sensitivity

Increase

0.75mg, then 1mg on separate uses if needed and tolerated

Status

Compounded and off-label; not the FDA-approved regimen

Nausea

Routine ondansetron pretreatment is not supported by the Vyleesi label

The approved regimen applies only to premenopausal women with acquired, generalized HSDD. Use in men, other populations, or with compounded dosing is off-label, and the label advises stopping after 8 weeks if symptoms do not improve.

Reconstitution & Route-Specific Preparation

Subcutaneous — 10mg Vial

BAC Water

1mL

Concentration

10mg/mL

1mg

10 units on a U-100 syringe

1.75mg

17.5 units on a U-100 syringe

Reconstitution Calculator

Intranasal Concentration Reference

Vial

10mg

Saline

1mL sterile, preservative-free 0.9% sodium chloride

Concentration

10mg/mL

0.1mL Pump

1mg per spray; approximately 10 sprays total

Intranasal bremelanotide is investigational and cannot be converted milligram-for-milligram from the approved subcutaneous dose. Historical nasal trials generally studied at least 7mg, often 20mg; the preparation math above is a concentration reference, not a validated nasal dosing protocol.

DIY Nasal Prep Essentials

Useful supplies for intranasal PT-141 prep

0.9% Sterile Saline AmpoulesPreservative-free single-use saline for nasal-prep workflows. Metered Nasal Spray BottlesUse a verified 0.1mL pump when calculating output per spray. 3mL Transfer SyringesUseful for measuring and transferring the saline volume. 70% Isopropyl AlcoholFor prep-area cleanup and clean handling around materials.

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Many users report a noticeable increase in sexual desire within roughly 45–90 minutes.
Reported duration is commonly described as 4–8 hours, with some users noticing effects beyond that window.
Some users describe stronger, more predictable effects from subcutaneous administration than from nasal use.
Some men report improved erection response, including when a PDE5 inhibitor alone felt inadequate.

Negative Reports

Nasal application is often described as unreliable or producing little noticeable effect.
Nausea and flushing are the most commonly mentioned limiting effects, especially at higher doses.
Some users feel no benefit, or notice a physical response without a meaningful increase in desire.
Delayed, prolonged, or unwanted arousal can make timing inconvenient for some users.

Stacking & Synergy

Relevant combinations and practical tracking

Relevant Combinations

PT-141 + PDE5 Inhibitor

This pairs central melanocortin signaling with a vascular erection pathway. A small controlled study found an enhanced erectile response with intranasal PT-141 plus sildenafil, but combined tolerability and cardiovascular context still matter.

PT-141 + Oxytocin

Community users sometimes pair PT-141 for desire or arousal with oxytocin for perceived connection. Controlled evidence for this combination is lacking, so outcomes and side effects should be tracked separately.

Free with login

Track in Journal

Track PT-141 with the markers that matter most for this compound.

Sexual desire and mental interest.
Physical arousal and erection response.
Onset, duration, and nausea.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

PT-141 Side Effects

Nausea is the main tolerability limit. In the Vyleesi trials, nausea occurred in 40% of treated patients; 13% needed an antiemetic and 8% discontinued because of nausea.

Bremelanotide temporarily raises blood pressure and lowers heart rate after each dose. The label reports peak effects 2–4 hours after dosing and return toward baseline within about 12 hours. It is contraindicated with uncontrolled hypertension or known cardiovascular disease.

Common Trial Effects

Nausea: 40%
Flushing: 20%
Injection-site reactions: 13%
Headache: 11%
Vomiting: about 5%

Important Label Warnings

Transient blood-pressure increase and heart-rate reduction.
Focal hyperpigmentation, which may not resolve after stopping.
Slower gastric emptying can alter absorption of oral medications.
Routine ondansetron pretreatment was not effective in the clinical program.

PT-141 Contraindications and Precautions

Contraindications

Uncontrolled hypertension.
Known cardiovascular disease.
Known hypersensitivity to bremelanotide or any formulation component.

Use Caution With

Pregnancy: discontinue if pregnancy is suspected; the label advises effective contraception during use.
Kidney or liver impairment, which can increase bremelanotide exposure.
Oral medications that depend on rapid absorption, particularly naltrexone-containing products.
A personal history of severe nausea or poor tolerance to melanocortin agonists.

Important Use Limits

Do not use more than one dose within 24 hours or more than 8 doses per month. More frequent use increases the risk of focal hyperpigmentation.

Regulatory Scope

Vyleesi is approved only for acquired, generalized HSDD in premenopausal women. It is not indicated for postmenopausal women, men, sexual-performance enhancement, intranasal use, or compounded formulations.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

We hate PT-141. It works differently than Viagra and related compounds as it works through the brain and not blood flow. The problem are the side effects which more often than not crashes the party, especially for females. Considering the cost and the fact the effects are completely random and not timed, you are better off getting a prescription via Amazon through their AI doc as generic Cialis is all of $8 for a month’s supply and doesn't have the side effect profile. So it's cheaper and works well and the onset effects are more reliable. Plus data is coming out that supports generic Cialis as being a helpful longevity tool for older men.

We see no reason to trial PT-141 unless you just want to give it a spin. It's probably a compound you try once and never buy again. Considering this does work on women while Cialis does not, gives it some credence, we'd probably point you both to Oxytocin instead.

We see no reason to choose PT-141 when far better, cheaper, and more predictable options exist. Potent in theory, but the risks, discomfort, and unreliability simply aren’t worth it in our opinion.